Introduction
============

Ventilator-associated pneumonia (VAP) is a frequent nosocomial infection among critically ill patients ([@B7]). Several clinical studies demonstrated the incidence of VAP is approximately 10% of all mechanically ventilated (MV) patients ([@B27]; [@B36]), with 13.1 VAPs per 1,000 MV-days reported by the International Nosocomial Infection Control Consortium (INICC) during 2010--2015 ([@B33]). These infections are associated with serious complications, prolonged hospitalization and length of mechanical ventilation, health-care costs, high mortality rate, and infection with multidrug-resistant (MDR) pathogens as well ([@B28]; [@B25]; [@B13]).

The isolation of one MDR pathogen has been identified as an independent predictor for increased mortality ([@B35]). Among various gram-negative isolates, the most commonly described MDR pathogens refer to *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and enterobacteriaceae, while MDR-*Acinetobacter baumannii* (MDR-AB) infections mostly consists of VAP ([@B2]; [@B3]). During recent decades, *A. baumannii*, a microorganism characterized by rapid development of resistance to the majority of antimicrobials, has been associated with extremely high mortality rate. Recent research indicated that the incidence of MDR-AB transmission was 315.4 cases/1000 ICU patient-days, and that the mortality rate of patients with MDR-AB ranged from 52 to 66% ([@B23]). Existing data reveal an important disparity in bacterial ecology between countries, and VAP management should be tailored on the basis of local microbiological data. *A. baumannii* is known to be endemic in Asian and European countries ([@B4]; [@B23]). However, data on Chinese are rare, so the aim of this study was to describe epidemiological and clinical characteristics of *A. baumannii* VAP (AB-VAP), and to identify the trend for drugs resisting to antibiotics.

MDR-AB infections are associated with high mortality because of not only affected patients' critical states, but also the difficulty in treatment ([@B5]). In many ICUs, MDR gram-negative pathogens with limited therapeutic options such as MDR-AB are commonly isolated ([@B6]). Increased incidence of MDR-AB triggers scholars enthusiasm in searching for new treatment options. For VAP patients caused by *A. baumannii*, the use of polymyxins (colistin or polymyxin B) or tigecycline is not recommended according to the 2016 guidelines of the American Thoracic Society and Infectious Diseases Society of America (ATS-IDSA) ([@B21]). Colistin application shows an upward tendency due to the emergence of MDR bacterial infections and VAP overseas ([@B34]). However, none of polymyxins or tigecycline has been widely approved for clinical use in China. In fact, using β-lactamase inhibitor combinations (cefoperazone/sulbactam, ampicillin/sulbactam) or meropenem as the basis of treatment programs accompanied by etilmicin or levofloxacin is frequently applied in empiric antibiotic therapies, but this approach has its defects of drug resistance and drug deficiency for *A. baumannii* in our ICU. The purpose of our study was to elucidate the effects of these empiric antibiotic regimens, and to provide experiential and clinical data for choosing medication regimens. According to the result for drug sensitivity, most VAP cases caused by *A. baumannii* belong to the group of MDR bacteria, so clinical treatment in our ICU mainly adopts combined medication.

In recent years, broad-spectrum antibiotics have been widely used in clinical practice, while the resistance rate of *A. baumannii* exhibits obvious increases ([@B29]; [@B4]). In clinic, the rates of isolating MDR or even extensively resistant *A. baumannii* are increased significantly ([@B16]). Studies have shown that the resistance rate of *A. baumannii* to most tested drugs is over 50% ([@B39]; [@B22]). Therefore, the combination of two or more drugs is often employed in treating MDR-AB infections. However, the sensitivity of drug combination has not been investigated in clinical practice, lacking experimental evidence about drug sensitivity to support the application of combining two or more antibiotics. In this study, 36 strains of MDR-AB were isolated from our ICU in 2017. Based on clinical medication principles, combined antimicrobial susceptibility tests were carried out *in vitro* to explore bacteriostatic effect of our empiric antibiotic regimens, and to provide certain evidence for clinical application. The 3-years retrospective study was conducted to describe the characteristics of AB-VAP, to determine clinical efficacy of four antimicrobials regimens and to study *in vitro* combined antimicrobial susceptibility tests.

Materials and Methods {#s1}
=====================

Setting and Study Design
------------------------

Our retrospective study was conducted in the general ICU of Suizhou Central Hospital Affiliated to Hubei University of Medicine from January 1, 2015 to December 31, 2017. Suizhou Central Hospital is a 1500-bed tertiary care comprehensive hospital, and receives about 59,500 admissions per year. The ICU of the hospital has 26 beds and covers all groups of medical and surgical cases. This study was approved by the Ethics Committee of Suizhou Central Hospital. The requirement for informed consent was waived considering its retrospective design.

The study included all adult patients who were MV for more than 48 h and developed VAP caused by *A. baumannii*. The first episode of AB-VAP or polymicrobial VAP was recorded for each patient. Patients with other previous or concurrent infections were included in the study. Eligible patients were collected on the basis of clinical culture results for the identification of MDR isolates.

Definitions
-----------

Ventilator-associated pneumonia definition conforms to the guidelines of Chinese Thoracic Society (CTS) and the ATS-IDSA ([@B29]; [@B3]). VAP would be confirmed if radiograph exhibited a new or persistent pulmonary infiltrate, and two or more of the following criteria were met: temperature more than 38°C or lower than 36°C, leukocytosis (peripheral blood leucocyte count \>10 × 10^9^/L) or leukopenia (peripheral blood leucocyte count \<4 × 10^9^/L) and the presence of purulent bronchial secretions. Pneumonia was considered to be ventilator-associated when the onset occurred 48 h after the initiation of MV, rather than before. Patients with no clinical symptoms or radiological evidence for infiltrate were excluded from the study. VAP onset date was defined as the day when the first clinical positive microbial cultures of aspirate were collected: ![](fphar-10-00092-e001.jpg)specimen cultures obtained by endotracheal aspiration cultures (ETA) \>10^5^ CFU/mL; or bronchoalveolar lavage cultures (BAL) \>10^4^ CFU/mL. MDR pathogens commonly resist to at least three classes of the following five antibiotics: cephalosporins, carbapenems, compound preparation containing β-lactamase inhibitor, fluoroquinolone, and aminoglycoside antibiotics. CPIS score is a retrospective calculation value for the studied cases.

Empirical Antimicrobial Agent Plan and Curative Effect Judgment
---------------------------------------------------------------

Dosage: sulbactam: following routine dose of 1.5 g every 8 h; meropenem: 1 g every 8 h; etilmicin: 100 mg every 12 h; and levofloxacin: 0.6 g daily. Four experiential treatment schemes were as follows: sulbactam + etilmicin, sulbactam + levofloxacin, meropenem + etilmicin, and meropenem + levofloxacin. All drug combination treatments lasted for at least 7--10 days. All patients in the study received appropriate antibiotic therapy.

Clinical outcome of AB-VAP came from comprehensive judgment based on clinical symptoms and clinical pulmonary infection scores (CPIS) of the patients. Cured: clinical symptoms were eliminated and sputum culture reached negative result; Improved: clinical symptoms were obviously relieved and CPIS score was declined when compared to that before combination therapy; Aggravated: clinical symptoms were worse and CPIS score was higher than that before combination therapy; Dead: VAP-related death was defined as that occurring during the treatment when pneumonia signs remained, or that due to septic shock. Effective treatment case number = cured + improved cases, Ineffective treatment cases = aggravated + dead cases.

Clinical Data Collection
------------------------

Information about AB-VAP episodes and treatment regimens which adopted β-lactamase inhibitor combinations (cefoperazone/sulbactam, ampicillin/sulbactam) or meropenem as the basis and combined with etilmicin or levofloxacin was collected, and clinical outcomes were analyzed to elucidate the effects of these empiric antibiotic regimens.

Clinical, biological, and treatment data were obtained through retrospectively revising patients' medical records and nosocomial infection management databases. Clinical data included age, sex, Acute Physiology and Chronic Health Evaluation (APACHE) II scores, ICU admission diagnosis, comorbidities, duration between MV application and VAP onset, and possible risk factors for MDR. Drug sensitivity data for *A. baumannii* to 16 antibiotics between the year of 2015 and 2017 were collected for analyzing drug resistance rate and trend. Data on antimicrobial therapy for AB-VAP group were recorded to assess the effectiveness.

Sensitivity Test on Drug Combination *in vitro*
-----------------------------------------------

Thirty six strains of MDR-AB were isolated from different patients in ICU of our hospital in 2017. Quality control strains were *Escherichia coli* ATCC25922 and *P. aeruginosa* ATCC27853. MH broth functioned as the culture medium.

Minimum inhibitory concentration (MIC) of single drug was determined in accordance with the method recommended by CLSI (M100-S23) ([@B9]). MIC values of sulbactam, meropenem, etilmicin, and levofloxacin against 36 strains of *A. baumannii* were determined using microbroth dilution method. Mueller-Hinton (MH) broth was diluted to a series of concentrations by double ratio. And all of the three antibiotics were diluted to 10 concentration gradients. The concentrations in sensitivity test on drug combination were 512, 256, 128, 64, 32, 16, 8, 4, 2, 1 (μg/mL). According to chessboard method, two different antimicrobial agents in combination with different concentrations and bacterial suspensory were add into 96-hole plates at 37°C for one night. Single drug MIC (MIC~A\ alone~ and MIC~B~ ~alone~) and MIC value of the optimal combination effect (MIC~A~ ~combined~ and MIC~B~ ~combined~) were recorded. Sensitivity test on drug combination usually adopts fractional inhibitory concentration (FIC) value to evaluate the effect of the combination. Calculating method and interpretation criterion for FIC index were as follows: FIC index = MIC~A~ ~combined~/MIC~A\ alone~ + MIC~B~ ~combined~/MIC~B\ alone~, synergistic: FIC≤0.5, addictive: 0.5\<FIC≤1, indifference: 1\<FIC≤2, and antagonistic: FIC\>2.

Statistical Analysis
--------------------

SPSS 24.0 and Excel were used for statistical analysis, and *P* \< 0.05 meant statistically significant difference. Qualitative variables were expressed as percentages, while quantitative variables as means ± standard deviations (SD) or medians.

Results
=======

Between January 2015 and December 2017, 3778 adult patients were admitted to our ICU and 3424 of them were MV. Among them, 237 (6.9%, 237/3424) conformed to diagnostic criteria for VAP. Besides, 85 episodes of VAP were attributed to *A. baumannii*, and the incidence of AB-VAP was approximately 35.9% (85/237). Of these 85 patients, 60 were included in our study while 25 others were excluded because VAP treatment time was not long enough or they underwent other treatments. And we analyzed clinical outcome of four different regimens of antibiotics combination: Meropenem or sulbactam with levofloxacin or etilmicin for these 60 cases. Additionally, we also detected the sensitivity for these four regimens based on 36 strains of MDR-AB from different patients in ICU of our hospital in 2017.

Clinical Characteristics of 60 Patients Treated for AB-VAP
----------------------------------------------------------

The mean age of the patients was 54.9 ± 12.8 years old (ranging from 29 to 83 years). The ratio of male to female was 4.5 (49 males and 11 females). APACHE II score was 24 ± 5. Among our enrolled patients, 24 (40%) were admitted owing to multiple trauma, 23 (38.3%) because of severe craniocerebral trauma, and 14 (23.3%) for severe nervous system disease. Fourteen patients (22.3%) had history of hypertension, seven (11.7%) had history of chronic obstructive pulmonary disease (COPD), six (10%) had history of other respiratory diseases, 4 (6.7%) had diabetes mellitus, 3 (5%) suffered coronary heart disease, and 3 (5%) endured digestive system disease. The mean duration of hospitalization for VAP was 7.4 ± 5.5 days, while mean span of ICU admission for VAP was 6.9 ± 4.8 days. Besides, the mean period from mechanical ventilation to VAP was 6.4 ± 4.8 days. The duration of mechanical ventilation was 14.6 ± 13.0 days, the duration for ICU stay was 22.7 ± 16.1 days, and that for hospital stay was 34.2 ± 18.4 days. Of the patients, 23 (33.3%) were treated with immunosuppressive therapy for more than 5 days, 14 (23.3%) with immunosuppressive therapy for 3--5 days, and 26 received no immunosuppressive therapy. Clinical characteristics and outcomes of all patients are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics of patients treated for *Acinetobacter baumannii* ventilator-associated pneumonia.

  Characteristics                                   
  ------------------------------------------------- -------------
  No.                                               60
  Age, mean ± SD (years)                            54.9 ± 12.8
  Female sex \[n (%)\]                              11 (18.3)
  Male sex \[n (%)\]                                49 (81.7)
  APACHE II score, mean ± SD                        24 ± 5
  **ICU admission diagnosis \[n (%)\]**             
      Multiple trauma                               24 (40)
      Severe craniocerebral trauma                  23 (38.3)
      Respiratory failure                           17 (28.3)
      Severe nervous system disease                 14 (23.3)
      Hemorrhagic shock                             7 (11.7)
      Various kinds of poisoning                    6 (10)
      Acute exacerbation of COPD                    4 (6.7)
      Other reasons                                 5 (8.3)
  **Comorbidities \[n (%)\]**                       
      Hypertension                                  14 (22.3)
      COPD                                          7 (11.7)
      Other respiratory diseases                    6 (10)
      Diabetes                                      4 (6.7)
      Coronary heart disease                        3 (5)
      Digestive system disease                      3 (5)
      None                                          30 (50)
      Days hospital admission to VAP, mean ± SD     7.4 ± 5.5
      Days ICU admission to VAP, mean ± SD          6.9 ± 4.8
  **Days MV to VAP, mean ± SD**                     6.4 ± 4.8
      Early-onset VAP \[n (%)\]                     7 (11.7)
      Late-onset VAP \[n (%)\]                      53 (88.3)
      Duration of MV, days, mean ± SD               14.6 ± 13.0
      Length of ICU stay, days, mean ± SD           22.7 ± 16.1
      Length of hospital stay, days, mean ± SD      34.2 ± 18.4
  **Receive immunosuppressive therapy \[n (%)\]**   
      \>5 days                                      20 (33.3)
      3--5 days                                     14 (23.3)
      None                                          26 (43.4)

APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; MV, mechanical ventilation

.

Antimicrobial Resistance of *Acinetobacter baumannii* of VAP From 2015 to 2017
------------------------------------------------------------------------------

Drug sensitivity of 60 strains of *A. baumannii* to 16 antibiotics between the year of 2015 and 2017 is shown in [Table 2](#T2){ref-type="table"}.

###### 

Drug sensitivity results on 60 isolates of *Acinetobacter baumannii* to 16 antibiotics between the year of 2015 and 2017 (%).

  Antibiotic                  2015 (19)   2016 (19)   2017 (22)   All (60)
  --------------------------- ----------- ----------- ----------- ----------
  Ceftazidime                 73.7        78.9        95.5        83.3
  Ciprofloxacin               68.4        78.9        95.5        81.7
  Gentamicin                  68.4        78.9        95.5        81.7
  Ceftriaxone                 73.7        84.2        95.5        85
  Furazolidin                 100         94.7        100         98.3
  Cefepime                    73.7        78.9        90.9        81.7
  Imipenem                    63.2        78.9        90.9        78.3
  Levofloxacin                63.2        73.7        86.4        75
  Ampicillin sulbactam        57.9        73.7        81.8        71.7
  Compound sulfamethoxazole   73.7        78.9        86.4        80
  Tobramycin                  78.9        84.2        95.5        86.7
  Amikacin                    63.2        68.4        72.7        68.3
  Piperacillin tazobactam     73.7        78.9        81.8        78.3
  Aztreonam                   100         94.7        100         98.3
  Cefotetan                   100         100         100         100
  Ampicillin                  100         100         100         100

S, sensitive; R, resistance

.

In this retrospective study, 60 strains of *A. baumannii* were all MDR bacteria. Resistance rates to the 16 antibiotics were all over 50%. Specifically, the resistance rate of *A. baumannii* to cefotetan (100%) and ampicillin (100%) was highest, followed by that to furazolidin (98.3%), aztreonam (98.3%), tobramycin (86.7%), ceftriaxone (85%), and ceftazidime (83.3%). The resistance rates to amikacin (68.3%) and ampicillin sulbactam (71.7%) were lowest, followed by that to levofloxacin (75%), imipenem (78.3%), and piperacillin tazobactam (78.3%). The details are shown in [Figure 1](#F1){ref-type="fig"}.

![Drug sensitivity of *Acinetobacter baumannii* to 16 antibiotics in 3 years (*n* = 60).](fphar-10-00092-g001){#F1}

[Figure 2](#F2){ref-type="fig"} shows that drug resistance rate of *A. baumannii* was much higher, with rising tends. Among them, the resistance rate to imipenem, ciprofloxacin, gentamicin, ampicillin sulbactam, and levofloxacin increased rapidly. In particular, the resistance to imipenem increased from 63.2 to 90.9%. While drug resistance to amikacin and piperacillin tazobactam grew relatively slowly.

![Drug sensitivity of *Acinetobacter baumannii* to 16 antibiotics between the year of 2015 and 2017 (*n* = 60).](fphar-10-00092-g002){#F2}

Therapeutic Effects of Different Combination Regimens for Four Antibiotics
--------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} shows therapeutic effect of four empirical schemes based on sulbactam or meropenem. In 60 cases, 38 adopted sulbactam as the basis, and 22 received meropenem. In this retrospective study, the most commonly used antibiotic therapy for AB-VAP was sulbactam combined with etilmicin (40% 24/60). Among these cases, sulbactam combined with etilmicin were effective in 18 (75%) and ineffective in 6 (25%). The adoption rate for sulbactam combined with levofloxacin, meropenem with etilmicin, and meropenem with levofloxacin was 23.3, 18.3, and 18.3%, respectively. The effective rate of sulbactam combined with levofloxacin was 71.4%, with an ineffective rate of 28.6%. The effective rate of meropenem combined with etilmicin was 72.7%, and the ineffective rate was 27.3%. The effective and ineffective rates of meropenem combined with levofloxacin was 63.6 and 36.4%, respectively. Therefore, sulbactam combined with etilmicin exhibited best effect. However, there was no statistical difference in therapeutic effect between sulbactam or meropenem. The details are shown in [Figure 3](#F3){ref-type="fig"}.

###### 

Therapeutic effects of four empirical schemes.

  Antibiotic therapy (n)                    Effective rate (%, n)   *P*-value
  ----------------------------------------- ----------------------- -----------
  Sulbactam + etilmicin (24)                75 (18/24)              0.809
  Sulbactam + levofloxacin (14)             71.4 (10/14)            
  Meropenem +etilmicin (11)                 72.7 (8/11)             0.647
  Meropenem + levofloxacin (11)             63.6 (7/11)             
  Sulbactam + etilmicin/levofloxacin (38)   73.7 (28/38)            0.649
  Meropenem + etilmicin/levofloxacin (22)   68.2 (15/22)            

![Therapeutic efficacy of four commonly used antimicrobial combinations for *Acinetobacter baumannii* ventilator-associated pneumonia (*n* = 60).](fphar-10-00092-g003){#F3}

Drug Sensitivity for Sulbactam or Meropenem Combined With Etilmicin or Levofloxacin *in vitro*
----------------------------------------------------------------------------------------------

As demonstrated in [Figure 4](#F4){ref-type="fig"}, when sulbactam or meropenem was combined with etilmicin or levofloxacin, respectively, the concentration-cumulative bacteriostatic percentage curve for each drug showed a left shift (better bacteriostatic effect). [Table 4](#T4){ref-type="table"} indicates that sulbactam or meropenem led to reduced MIC~50~ and MIC~90~ of the 36 strains, and enhanced antimicrobial activities when combined with etilmicin, especially sulbactam combined with etilmicin. After combined with etilmicin, sulbactam reduced MIC~50~ and MIC~90~ to 1/2. MIC~50~ and MIC~90~ for etilmicin decreased significantly. After combined with levofloxacin or etilmicin, MIC~50~ and MIC~90~ of meropenem were 1/2 of that in single application. After combined with sulbactam or meropenem, the MIC~50~ of levofloxacin was 1/2 of that in single application. The peak value of MIC obviously shifted to the left compared to that in single usage. FIC results in [Table 5](#T5){ref-type="table"} suggested that sulbactam or meropenem combined with etilmicin or levofloxacin imposed additive or unrelated effect, without any antagonistic effects. For the combination of sulbactam with etimicin, the synergistic effect was 2.78%, the additive effect was 63.89%, and the unrelated effect was 33.33%; when it came to its combination with levofloxacin, the additive effect accounted for 41.67% while the unrelated effect for 58.33%.

![Concentration accumulated inhibition percentage curve of the antibacterial activity against multidrug-resistant *Acinetobacter baumannii* (*n* = 36).](fphar-10-00092-g004){#F4}

###### 

MICs of four antibiotics against 36 isolates of multidrug-resistant *Acinetobacter baumannii* (μg/mL).

  Antibiotics                Alone          Combined                                
  -------------------------- -------------- ---------- ------- -------- ----- ----- --------
  Sulbactam + etilmicin      Sulbactam      64         128     8--128   32    64    8--128
                             Etilmicin      \>512      \>512   512      16    512   1--512
  Sulbactam + levofloxacin   Sulbactam      64         128     8--128   64    64    1--128
                             Levofloxacin   8          16      4--128   4     16    2--64
  Meropenem +etilmicin       Meropenem      32         64      2--64    16    32    2--64
                             Etilmicin      \>512      \>512   512      512   512   2--512
  Meropenem + levofloxacin   Meropenem      32         64      2--64    16    32    1--64
                             Levofloxacin   8          16      4--128   4     16    1--64

###### 

The distribution (%) of FIC for sulbactam or meropenem combined with etilmicin or levofloxacin to multidrug-resistant *Acinetobacter baumannii* strains (*n* = 36).

  Antibiotics                FIC≤0.5    0.5\<FIC≤1   1\<FIC≤2     FIC\<2
  -------------------------- ---------- ------------ ------------ ----------
  Sulbactam + etilmicin      2.78 (1)   63.89 (23)   33.33 (12)   0.00 (0)
  Sulbactam + levofloxacin   0 (0)      41.67 (15)   58.33 (21)   0.00 (0)
  Meropenem +etilmicin       0 (0)      30.56 (11)   69.44 (25)   0.00 (0)
  Meropenem + levofloxacin   2.78 (1)   38.89 (14)   58.33 (21)   0.00 (0)

Discussion
==========

Ventilator-associated pneumonia is a frequent nosocomial infection in critically ill patients and a common complication in MV cases ([@B2]). It is the second most common nosocomial infection in the ICU, most common in MV patients ([@B1]; [@B19]). VAP is estimated to occur in 9--27% of all MV patients. In our study, the incidence of VAP was approximately 6.9% (237/3424) among all MV patients. VAP is associated with increased hospital stay, health-care costs, mortality, and infection with MDR pathogens (American Thoracic Society and Infectious Diseases Society of America, 2005; [@B19]). VAP could be classified into early-onset and late-onset types, and early-onset VAP (\<5d since hospitalization) has been commonly associated with better prognosis, in which bacteria are more susceptible to antibiotic therapy. On the other hand, late-onset VAP refers to VAP occurring 5 or more days after hospital admission, and is associated with higher morbidity, mortality, and MDR pathogens. Of the 60 patients, 7 (11.7%) belonged to early-onset VAP while 53 (88.3%) to late-onset VAP.

Acinetobacter species have become increasingly common in ICUs over the past two decades, causing serious infections. Organism is widely distributed in nature and survives on both moist and dry surfaces ([@B12]; [@B23]). Data regarding to VAP caused by *A. baumannii* in China are limited. In this retrospective study, we assessed clinical characteristics and antimicrobial resistance of *A. baumannii* in VAP on the basis of the patients between the year of 2015 and 2017 in our ICU. In our research, the incidence of AB-VAP was approximately 35.9% in all VAP patients. *A. baumannii* has been considered to be a prevailing pathogen causing VAP, leading to high morbidity and mortality among patients in ICUs ([@B17]; [@B30]). *A. baumannii* usually is a MDR bacteria. So AB-VAP patients frequently face high mortality and limited therapeutic options ([@B5]).

In this retrospective study, 60 strains of *A. baumannii* were all MDR bacteria. *A. baumannii* represents a major pathogen of VAP in ICU ([@B11]), and shows high rate of resistance to antimicrobial agents and multiple resistance, which should be noted during clinical process. According to the results on drug sensitivity to 16 commonly used antibiotics, the resistance rate of *A. baumannii* to cefotetan and ampicillin reached 100%, while such figure to furazolidin and aztreonam was over 95%. Comparatively, the resistance rates to amikacin and ampicillin sulbactam were lowest, but still reached 68.3 and 71.7%, respectively. *A. baumannii* resists all antibiotics currently used and such resistance shows an increasing tendency. Among others, its resistance rate to imipenem, ciprofloxacin, gentamicin, ampicillin sulbactam, and levofloxacin increases rapidly. In particular, the resistance to imipenem has increased from 63.2 to 90.9% in 3 years in our study, consistent with the findings from previous studies ([@B10]). However, carbapenems (imipenem, meropenem, or doripenem) used to be an excellent choice for serious infections, but the outbreaks of carbapenem-resistant *A. baumannii* infection limit such therapeutic options ([@B26]; [@B8]).

For VAP patients caused by *A. baumannii*, the 2016 guidelines of the ATS-IDSA recommended to adopt polymyxins (colistin or polymyxin B) or tigecycline ([@B21]). Colistin application has increased due to the emergence of MDR bacterial infections and VAP overseas ([@B15]; [@B34]). Statistical data from meta analysis showed that colistin appeared effective and safe in treating MDR gram-negative bacteria VAP ([@B18]). Meanwhile, tigecycline is also considered to be one of few therapeutic options for MDR-AB ([@B24]). However, its role in treating *A. baumannii* bacteraemia remains controversial. Prospective study has demonstrated that tigecycline plus prolonged infusion of standard dose of imipenem/cilastatin exhibits fine clinical effect on patients with MDR-AB VAP ([@B20]). However, some other studies indicated that tigecycline is associated with higher mortality when compared to control antibiotics ([@B32]). Moreover, neither polymyxins nor tigecycline has been widely approved in China due to many aspects, such as economy, drug and hospital management, etc. So large-scale drug resistance monitoring and clinical application data for polymyxins or tigecycline are rare. At present, commonly used antibiotics for *A. baumannii* include β-lactamase inhibitor combinations (cefoperazone/sulbactam, ampicillin/sulbactam), carbapenem antibiotics (meropenem, imipenem), tetracycline antibiotics (minocycline), aminoglycoside antibiotics (etimicin, amikacin), and other quinolones, as well as the third and fourth generations of cephalosporins, which have antibacterial activity targeting *A. baumannii* ([@B14]). In fact, the combination regimens of two or even three drugs are often adopting in treating MDR-AB infections. And the most common combination regimen is based on β-lactamase inhibitor combinations or carbapenem antibiotics. Sulbactam or meropenem as the basis of treatment programs combined with etilmicin or levofloxacin is frequently selected as empiric antibiotic therapy when facing AB-VAP-related drug resistance and drug deficiency in our ICU, though drug resistance was strong and resistance rate of *A. baumannii* to commonly used antibiotics increased rapidly.

In this retrospective study, we analyzed clinical outcome and drug sensitivity for four different combination regimens based on antibiotics: Meropenem or sulbactam with levofloxacin or etilmicin. In 60 AB-VAP cases, antibiotics combination was effective for most cases. Of the cases, 38 received sulbactam as basis, and 22 adopted meropenem as the basis. The most commonly used antibiotic therapy for AB-VAP was sulbactam combined with etilmicin (40% 24/60). The efficiency rate of these four experiential treatment schemes were more than 60%, and the figure for sulbactam combined with etilmicin even reached 75%. A previous study indicated that colistin or ampicillin-sulbactam could reach similar cure rates in treating carbapenem-resistant AB-VAP, but that colistin was associated with higher rates of microbiologic failure, reduction in renal function, and increased 30-day mortality ([@B38]). In this study, clinical results indirectly manifested that antibiotics combination against *A. baumannii* (AB) infection in VAP obtained better outcome: According to the result of drug sensitivity in [Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}, most VAP caused by *A. baumannii* were multi-drug-resistant bacteria, and all 60 strains of *A. baumannii* (in the study) were MDR bacteria from reports microbiological laboratory. However, in these 60 cases of AB-VAP, the combinations between 4 antibiotics were effective in most cases. Therefore, sulbactam or meropenem as the basis of treatment programs combined with etilmicin or levofloxacin may be an efficacious alternative in treating AB-VAP.

To further explore potential mechanisms, drug sensitivity of 36 clinical isolates of MDR-AB were tested *in vitro* to four antiseptic drugs in both single application and drug combination. Sulbactam is a semi-synthetic β-lactamase inhibitor and has direct bacteriostatic effect on *A. baumannii*. Specific *in vitro* activity of sulbactam against Acinetobacter spp. is related to its affinity to penicillin-binding proteins ([@B31]). Reportedly, the combination of minocycline with cefoperazone-sulbactam exhibited significant synergistic activity against carbapenem-resistant *A. baumannii in vitro* ([@B31]). *In vitro* drug sensitivity results from [@B37] indicated that cefoperazone/sulbactam in combination with minocycline, meropenem and levofloxacin generated synergistic and additive *in vitro* bacteriostatic action on carbapenem-resistant *A. baumannii*. In our study, when sulbactam or meropenem was combined with etilmicin or levofloxacin, respectively, concentration-cumulative bacteriostatic percentage curve for each drug showed a left shift. After combining with etilmicin, MIC~50~ and MIC~90~ of sulbactam decreased 1/2 and MIC~50~ and MIC~90~ of etilmicin also decreased significantly, consistent with conclusion in previous studies ([@B31]; [@B37]). Sulbactam or meropenem showed significantly reduced MIC~50~ and MIC~90~, and enhanced antimicrobial activities when combined with etilmicin or levofloxacin. FIC results suggested that the combination of sulbactam or meropenem with etilmicinor levofloxacin mainly produced additive or unrelated effect, without any antagonistic effects. The sensitivity test for drug combination may guide clinical medication. According to *in vitro* sensitivity test, the combination of antibiotics against *A. baumannii* (AB) infection in VAP had higher sensitivity than single antibiotic application: MIC~50~ and MIC~90~ of four antibiotics after the combination were correspondingly decreased compared to those in single antibiotic application. The advantages of combination therapy were more prominent in the combination of sulbactam with etimicin. FIC results suggested the additive effect was 63.89% in such combination regimen.

Conclusion
==========

Resistance rate of *A. baumannii* to commonly used antibiotics has increased rapidly. *In vitro* sensitivity test on drug combination is helpful choosing antimicrobial treatment regimens. Sulbactam or meropenem as the basis of treatment programs combined with etilmicin or levofloxacin can be an efficacious alternative in treating *A. baumannii* VAP. Sulbactam combined with etimicin is recommended for *A. baumannii* VAP in Suizhou, Hubei, China. Sensitivity test on drug combination may contribute to the formulation of clinical medication plans to some extent.
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